GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline has announced that China’s National Medical Products Administration granted Breakthrough Therapy Designation for Blenrep in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma, based on promising phase III DREAMM-7 trial results. This designation aims to expedite the development of therapies where substantial improvements over existing options are demonstrated. The trial showed significant progression-free survival benefits and consistent safety profiles, addressing the growing need for effective treatments in China’s increasing multiple myeloma cases.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
